Evidence map›Paper›PMID 33022008›Full record

ArticlePloS one2020

Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites.

Sameh S M Soliman, Tasneem B Alhamidi, Shifaa Abdin, Ahmed M Almehdi, Mohammad H Semreen, Razan B Alhumaidi, Sarra B Shakartalla, Mohamed Haider, Mohamed I Husseiny, Hany A Omar

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Scientific reports · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Sameh S M SolimanResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.ORCID 0000-0002-7691-615X
Tasneem B AlhamidiResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.
Shifaa AbdinResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.ORCID 0000-0002-7622-9683
Ahmed M AlmehdiDepartment of Chemistry, College of Sciences, University of Sharjah, Sharjah, UAE.
Mohammad H SemreenResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.
Razan B AlhumaidiResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.
Sarra B ShakartallaResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.
Mohamed HaiderResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.ORCID 0000-0003-3150-9275
Mohamed I HusseinyFaculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Hany A OmarResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, UAE.
University of Sharjah · AEZagazig University · EGBeni-Suef University · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biogenic synthesis of nanoparticles provides many advantages over synthetic nanoparticles including clean and non-toxic approaches. Nanoparticle-based application for the development of diagnostics and therapeutics is a promising field that requires further enrichment and investigation. The use of biological systems for the generation of gold nanoparticles (AuNPs) has been extensively studied. The search for a biocompatibility approach for the development of nanoparticles is of great interest since it can provide more targeting and less toxicity. Here, we reported a bio-reductive approach of gold to AuNPs using metabolites extracted from mammalian cells, which provided a simple and efficient way for the synthesis of nanomaterials. AuNPs were more efficiently synthesized by the metabolites extracted from breast cancer (MCF7) and normal fibroblasts (F180) cells when compared to metabolites extracted from cell-free supernatants. The metabolites involved in biogenic synthesis are mainly alcohols and acids. Spectroscopic characterization using UV-visible spectra, morphological characterization using electron microscopy and structural characterization using X-ray diffraction (XRD) confirmed the AuNPs synthesis from mammalian cells metabolites. AuNPs generated from MCF7 cells metabolites showed significant anticancer activities against MCF7 and low toxicity when compared to those generated from F180 cells metabolites. The results reflected the cytotoxic activities of the parent metabolites extracted from MCF7 versus those extracted from F180. Comparative metabolomics analysis indicated that MCF7-generated AuNPs harbored tetratetracontane, octacosane, and cyclotetradecane while those generated from F180 harbored a high percentage of stearic, palmitic, heptadecanoic acid. We related the variation in cytotoxic activities between cell types to the differences in AuNPs-harboring metabolites. The process used in this study to develop the nanoparticles is novel and should have useful future anticancer applications mainly because of proper specific targeting to cancer cells.

Indexed as

Antineoplastic AgentsBreast NeoplasmsDrug CompoundingDrug Screening Assays, AntitumorFemaleFibroblastsGoldHumansMCF-7 CellsMetabolomicsMetal NanoparticlesNanotechnologyAntineoplastic AgentsGold

Identifiers

PMID33022008
PMCPMC7537904
OpenAlexW3092553761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.